Adoptive Transfer Of EBV Specific T-Cells For Treatment Of Primary And Rituxan Resistant EBV Lymphomas Following Allogeneic Stem Cell Transplants (HSCT): Clinical, Viral And Immunologic Corelates  by Doubrovina, E. et al.
S220 Poster Session IGraft versus host disease (GVHD) is a significant cause of morbid-
ity and mortality after allogeneic hematopoietic stem cell transplan-
tation. In vivo quantitative T-cell depletion using CAMPATH-1H
(anti-CD52) has been explored in an effort to prevent acute
GVHD. Recently, a regimen of total lymphoid irradiation (TLI)
and anti-thymocyte globulin (ATG) has been shown to polarize T-
cells towards an inhibitory phenotype potentially reducing the risk
for GVHD. However, these strategies may lead to impaired post-
transplant immune reconstitution, increased risk of tumor relapse
and opportunistic infection. We compared the immune recovery of
20 patients undergoing reduced intensity conditioning with low
dose CAMPATH and an initial cohort of 5 patients treated with
TLI/ATG. Conditioning with CAMPATH resulted in a significant
depletion of CD4 and CD8 T-cells in the early post-transplant pe-
riod and persistence of CD4 T-cell depletion for 6 months. Follow-
ing TLI/ATG, there was a persistent depletion of CD4 T-cells with
no significant decrease in CD8 T-cells. CAMPATH was associated
with a decrease in CD45RO+ memory T-cells in the early post-
transplant period (27.2 to 5.7%, p5 0.03). T-cell recovery in early
post-transplant following TLI/ATG was associated with a rise in
the relative percentages of naive T-cells (CD45RA+) (39 to 61.3%;
p5 0.04), central memory (CD45RO +CD62L +CCR7+) (CM)
(12 to 32.8%; p5 0.05), and a significant change in the central mem-
ory:effector memory (CD45RO +CD62L-CCR7-) (EM) ratio (0.2
to 1.0). The mean percentage of regulatory T-cells
(CD4 +CD25 + FoxP3+) rose in the early post-transplant period fol-
lowing both regimens (p\0.03). Functional analyses demonstrated
that the T-cell proliferative response to Phytohemagglutinin (PHA)
was profoundly depressed following CAMPATH with mean SI de-
creasing from 34 pre-transplant to 1.4 Day 30. Treatment with
TLI/ATG resulted in no significant change in response to PHA. As-
sessment of T-cell polarization after stimulation with PMA/ionomy-
cin, recipient derived dendritic cells (DCs) or third party DCs
demonstrated a rise of CD8 +T-cells expressing IL-4 and IL-10
consistent with a suppressor phenotype. In summary, both CAM-
PATH and TLI/ATG result in CD4 +T-cell depletion, but TLI/
ATG resulted in persistence of memory cells, relative preservation
of CM as compared to EM and intact response to mitogens. TLI/
ATG therapy was associated with a more modest level of functional
T-cell depletion characterized by Tc2 polarization.169
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CD4 + CD25highFoxP3+ regulatory T cells (Tregs) play a central
role in immunologic homeostasis and are able to induce tolerance af-
ter allogeneic hematopoietic stem cell transplantation (alloPBSCT).
Polyclonal rabbit-anti-human antithymocyte globulins (rATG) are
widely used to prevent and treat Graft-versus-Host-Disease
(GvHD) after alloPBSCT. Their mechanism of action has been
thought to be mainly mediated by CD4+ effector T cell depletion
and complement-dependent lysis. Interestingly, recent in vitro data
have suggested that rATGs might increase the ratio or number of
regulatory T cells. But so far, it is not knownwhether such effects ex-
ist in humans in vivo.
Here, we present the data of a prospective pilot study in which we
analyzed the influence of rATGs on the reconstitution of peripheral
CD4+/CD25high/FoxP3 + Tregs after alloPBSCT.
Ten patients were divided into two groups depending on the re-
quirements of the respective alloPBSCT protocol: those who re-
ceived one type of rATG during conditioning therapy from day -3
to -1 (rATG; n5 6) and those who were conditioned without
rATG administration (non-rATG; n5 4). Patients of the rATG
group received a total dose of either rATG-Fresenius 30 mg/
kgBW (n5 3) or rATG-Genzyme 6 mg/kgBW (n5 3) respectively.
All patients received peripheral hematopoietic stem cells fromHLA-
matched donors and the grafts contained comparable median num-bers of CD3+ and CD34+ in both patient groups (table 1). GvHD
prophylaxis consisted of Mycophenolate Mofetil and Cyclosporine
A in all patients and antiviral prophylaxis was with acyclovir. Periph-
eral blood samples were taken before conditioning and after al-
loPBSCT at distinct time points (day +30, +60, +90 and +150) and
immune cells were analyzed by flow cytometry. An in vitro suppres-
sion assay of d + 150 Tregs from cryopreserved samples was done
with CD4 +CD25+ selected Tregs and CD4 +CD25- selected
CSFE labelled autologous responder T cells.
In summary, we found a more than 3-fold stable increase of rela-
tive Treg numbers in rATG treated patients after alloPBSCT com-
pared to the control. Day + 150 Tregs suppressed the responder cell
proliferation effectively in the in vitro assay.
Taken together, our results rise first evidence that rATG treat-
ment leads to increased, functional active CD4+/CD25high/
FoxP3 + Tregs in humans after allogeneic stem cell transplantation
which supports the thesis that rATG exhibit their immunomodula-
tory activity by additional mechanisms beyond simple cell depletion.
Table 1. Patient characteristics and transplantation parame-
ters
Baseline parameters rATG non-rATGPatients 6 4Age (median) 37 - 68 (61) 48 - 67 (62)Diagnosis MM, MCL, CLL, ALL AML (n5 3), OMFConditioning regimenRIC 5 3Standard 1 1Transplanted cell
numbers x 106/kg
BW recipient,
(median)CD341 PBSC 1.85 - 11.0 (7.6) 4.91 - 9.47 (7.3) p 0.47CD31 T cells 150 - 480 (219) 120 - 540 (175) p 0.38MRD: matched related donor; MUD: matched unrelated donor; RIC:
Reduced Intensity Conditioning (Treosulfan / Fludarabin or Cyclopho-
spamide/Fludarabin or 2 Gy-Total-Body-Irradiation/ Fludarabin); Stan-
dard conditioning (Cyclophosphamide/12 Gy-Total-Body-Irradiation).
BW: body weight; AML: acute myeloid leukaemia; OMF: osteomyelofib-
rosis; CLL: chronic lymphocytic leukaemia; ALL: acute lymphoblastic
leukaemia; MCL: mantle cell lymphoma; MM: multiple myeloma. PBSC:
peripheral blood stem cells. Cellular subpopulations of the transplanted
grafts were calculated to the respective recipients body weight. Statisti-
cal analysis by SPSS.170
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EBV lymphomas (EBV-L) arising postHSCT that persist or recur
following Rituxan therapy are often fatal. We analyzed treatment
with EBV-specific T-cells (EBV-CTL) in 22 patients (pts) who de-
veloped EBV-L following HLA-matched (N5 8) or non-identical
N5 11 T cell depleted (N5 17) or unmodified (N5 3) HSCT or
cord blood grafts (N5 3). All pts had clinical and radiologic evidence
of rapidly growing tumors ofWaldeyer’s ring and/or intestines, liver,
lung or CNS and rising blood levels of EBV DNA. Biopsies showed
B cell, EBV+ lymphoma in 20 pts that were monoclonal (12/12
tested) and usually of donor origin (11/12 tested). Of 22 pts, 14
had failed (N5 10) or recurred (N5 4) following Rituxan treat-
ment. EBV-CTLwere grown from donorT-cells sensitized with au-
tologous EBVBLCL transformed by EBV strain B95.8 (B95.8
EBVBLCL) and tested for specificity, lack of alloreactivity and ste-
rility. Treatment included 3 weekly infusions of EBV-CTL (106 T
Poster Session I S221cells/kg/Dose). Tumor responses, EBV DNA levels and quantita-
tions of tetramer+, IFNg+ EBV-specific T-cells and EBV CTLp
by limiting dilution analysis (LDA) were monitored. Infusions
were well tolerated; no pt developed GVHD.
Of the 22 pts, 3 died too early to be evaluated (\10 days). Of 6
pts primarily treated with EBV-CTL, 5 (83%) achieved CR, ver-
sus 7/13 (53%) who failed Rituxan. The CR rate was similar in pts
on no immunosuppressives or on Sirolimus or Calcineurin inhib-
itors alone (75% with; 67% without), but was lower for pts on ste-
roids for GVHD or cerebral edema (33%) than for pts off steroids
(69%). Pts with single sites of disease fared better than pts with
multiple sites (75% vs. 42% CR). However, all sites of disease, in-
cluding CNS, were comparably responsive to therapy. CTLp fre-
quencies rose 10-200 fold by 2-3 weeks post infusion in pts
achieving CR and were temporally associated with disease regres-
sion and clearance of EBV DNA. Such increases were not seen in
any pt with PD. EBV CTLs inducing CRs in 8 pts studied lysed
both B95.8 EBVBLCL and spontaneous EBV+ BLCL transform-
ants (S-EBV BLCL) isolated from the pt’s blood or involved tis-
sues; EBV CTL given to 3 non-responders on no
immunosuppression lysed B95.8+ BLCL, but not S-EBVBLCL
of donor origin isolated from the pt.
While EBVCTL can induce durable remissions of EBV lym-
phoma post HSCT, efficacy may be compromised in Rituxan refrac-
tory disease, by ongoing steroid treatment or by failure of the
EBVCTL to recognize the endogenous EBV the pt’s lymphoma.171
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Profound depletion of T and B cells is a fundamental prerequisite
for haploidentical transplantation and allows tominimizeGvHDde-
spite HLA incompatibility. However, posttransplant recovery of do-
nor derived T cells is delayed after various graft manipulation
procedures and may result in severe infections. Methods to improve
this recovery are of importance. Here we present immune reconsti-
tution data in patients who received CD3/CD19 depleted stem cells
in combination with melphalan based or standard conditioning reg-
imens. 32 patients with ALL(n5 14), AML/MDS n5 17),
CML(n5 1) were included. T- and B-cells were directly depleted
using antiCD3/antiCD19 coatedmagneticmicrobeads and the Clin-
iMACS device. The patients received either TBI or Bu i.v. and
OKT3(n5 9) or a reduced intensity conditioning (‘‘RIC’’: Mel
140 mg/m2, Flud 160 mg/m2, TT 10 mg/kg, OKT3, n5 23).
Absolute numbers of lymphocyte subsets per microliter on day 90
were compared within these both groups and with a historical con-
trol group (patients with leukemias who received CD34 selected
grafts and TBI or Bu based standard conditioning regimen in com-
bination with ATG, n5 28).
CD3 + 4+, CD3 + 8+ and total numbers of CD3+ of patients after
CD3/CD19 depletion were significantly higher in the RIC-group
than in the TBI/Bu-group (mean: 85.83 vs. 38.84; 133.46 vs.
19.69; 270.27 vs. 63.99; p\0.05, t-test).
Comparisonwith thewholeCD34historical group showed a faster
recovery of CD3 + 4+ in patients with CD3/19 depletion and RIC
(104.26 vs. 54.22; p5 0,034) but no significant difference in
CD3 + 8+ and CD3+. Furthermore, subgroups of the CD34 histor-
ical population were compared: patients with CD3/19 depletion
and RIC had a significantly faster recovery of CD3 + 4+, CD3 + 8+
and CD3+ than CD34 patients with TBI (104.26vs. 25.48;
133.46vs. 43.17; 270.27 vs. 65.86; p\0.05) but had no advantage
over CD34 patients with non-TBI conditioning.
Conclusions: the type of graft manipulation appeared to have an
influence on the speed of CD4+ recovery (CD3/19 deple-
tion.CD34 selection). Moreover, the use of TBI had a negative
impact on all T cell subsets: patients with TBI had a slower recov-
ery than patients with non-TBI conditioning, independent from
graft manipulation procedures and probably due to thymic dam-
age. Thus, the use of RIC-protocols in combination with CD3/CD19 depletion may help to speed up the immune recovery after
haploidentical transplantation. Further studies are warranted to
evaluate the risk of relapse.172
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Graft versus Host Disease (GVHD) and infectious complications
are the main cause of morbidity and mortality after allogeneic blood
or marrow transplantation (allo-BMT). Currently, there is no objec-
tive laboratory assay to assess the level of immunereactivity to poten-
tially predict the risk of complications in allo-BMT patients. The
Cylex ImmuKnow assay is approved by theUSFood andDrug Ad-
ministration for detection of cell mediated immunity in immunosup-
pressed individuals. This assay measures immune response to
stimulation by detecting ATP synthesis in CD4 T cells following
phytohemagglutinin (PHA) stimulation. We prospectively studied
PHA-induced ATP release in 20 allo-BMT patients weekly from
day +15 until day +100 post-transplantation. We tested 224 blood
samples with an average of 11.2 per patient (SD 1.8). Patients re-
ceived grafts from matched unrelated (MUD, n5 11 [55%]),
matched related (MRD, n5 8 [40]) and syngeneic donors (n5 1).
Myeloablative and nonmyeloablative conditioning regimens were
used in 13 (65%) and 7 (35%) patients, respectively. 12 patients
(60%) developed GVHD requiring treatment, 2 (10%) developed
GVHD which did not require treatment, and 6 (30%) did not de-
velop any GVHD. Cyclosporine levels (n5 19) did not correlate
with ATP response, nor did the graft composition (CD34+ cells/
kg or the CD3+ cells/kg). Further, we determined that the maximum
ATP level was not a significant predictor of GVHD incidence, nor
was the maximum fold increase over baseline. However, we observed
worse outcomes in patients who had sustained low ATP levels as de-
fined by 3 consecutive measurements of ATP\75 ng/mL.We found
a significant correlation between persistently suppressed ATP levels
and death (p5 0.013). In all patients who died (n5 7), ATP levels
were persistently low and did not recover. In contrast, all 9 patients
who exhibited ATP levels .75ng/ml are alive. Patients who main-
tained an average of .100 ng/ml ATP (mean 235 ng/ML, range
114-402 ng/mL) at monthly intervals did not have GVHD (n5 6)
or require therapy for GVHD (n5 2). Conversely, patients with
ATP levels \100 ng/mL at monthly intervals were treated for
GVHD (mean 84.4 ng/mL, range 24-318ng/mL). Our data suggest
that a persistent immunocompromised state in BMT recipients is as-
sociated with poor outcome. A larger study is warranted to analyze
the utility of the Cylex ImmuKnow assay in BMT patients, which
may enable us to predict outcomes and tailor immunosuppressive
therapy.173
TEMPORARY LICENSING OF HYPORESPONSIVE NK CELLS FOLLOWING
ALLOGENEIC HCT IS NOT AFFECTED BY T-CELLS IN THE STEM CELL AL-
LOGRAFT
Tarek, N.1, Yu, J.2, Venstrom, J.M.3, Hsu, K.C.3 1Memorial Sloan-Ket-
tering Cancer Center, New York, NY; 2Sloan-Kettering Institute for Can-
cer Research, New York, NY; 3Memorial Sloan-Kettering Cancer Center,
New York, NY
InHLA-matchedT-cell depleted (TCD)HCT, recipients lacking
class I ligands for donor inhibitory KIR have lower relapse and
higher survival. The ‘‘missing ligand’’ effect on clinical outcome is
likely due to temporary licensing post-transplant of the normally hy-
poresponsiveNK cells expressingKIR for non-selfHLA ligands. Be-
cause the KIR-expressing NK repertoire following HCT can be
affected by T-cells in the allograft, we examined NK functional re-
constitution in recipients of unmodified HCT. We assessed NK
function in 10 patients following unmodified stem cell
